In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

L'Oreal Critical Wavelength Criticism Based On "Flawed" Analysis - P&G

This article was originally published in The Rose Sheet

Executive Summary

L'Oreal used a "flawed technical analysis" in assessing the critical wavelength method as a UVA sunscreen testing assay, Procter & Gamble asserts in May 2 comments to FDA.

You may also be interested in...



UVA Protection Provided By 10% Of Sunscreens Tested - Researcher Diffey

Only six of 59 commercially available sunscreens met the critical wavelength standard of +/-370 nm to establish efficacy against UVA light in a study conducted by Brian Diffey, Newcastle General Hospital, England, et al., and published in the December Journal of the American Academy of Dermatology.

UVA Protection Provided By 10% Of Sunscreens Tested - Researcher Diffey

Only six of 59 commercially available sunscreens met the critical wavelength standard of +/-370 nm to establish efficacy against UVA light in a study conducted by Brian Diffey, Newcastle General Hospital, England, et al., and published in the December Journal of the American Academy of Dermatology.

L'Oreal

Company developing in vitro UVA sunscreen testing method to validate in vivo Persistent Pigment Darkening assay, the company tells FDA in a recent letter reiterating its preference for the PPD method in measuring UVA protection levels. Having both validated methods "should accurately and quantitatively measure the corresponding protection benefits," L'Oreal says. The company also voices its support for separate UVA and UVB labeling; FDA is considering leaving SPF as the primary indicator of sunscreen protection (1"The Rose Sheet" Feb. 14, p. 6)

Related Content

UsernamePublicRestriction

Register

RS008051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel